shelf(0)

No. 025 · Metabolic · Metabolic Peptide

5-Amino-1MQ

5-Amino-1-methylquinoliniumNNMT inhibitor

C Tier C · Animal data how tiers work →
  • Not FDA approved
  • WADA ✗ S0
  • Not a peptide
Compare Cite
Fingerprint not a peptide
5-Amino-1MQ (no defined sequence)

5-Amino-1MQ is not a peptide, so it has no amino-acid sequence. This ring motif is decorative.

01

Evidence

  1. D In vitro
  2. C Animal
  3. B Human pilot
  4. A RCT
  5. S Approved

TIER C — Evidence comes mostly from animal studies.

Evidence is from diet-induced obese mouse studies (Neelakantan et al., Biochem Pharmacol 2018); no published human studies.

Tiers rate the strength of published evidence — not effectiveness, safety, or a recommendation.

02

At a glance

Molecular weight
159.2 Da
Formula
C10H11N2+
Routes studied
Oral Routes used in published research
FDA
Not approved
WADA
Prohibited · S0 Non-approved substances
03

Overview

A small-molecule NNMT inhibitor that blocks nicotinamide N-methyltransferase, boosting NAD+ salvage and cellular energy metabolism. Explored for obesity and metabolic dysfunction.

Research status Preclinical research only (cell and diet-induced obese mouse studies); no published human clinical trials

04

Mechanism

5-Amino-1MQ is a cell-permeable inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that degrades the NAD+ precursor nicotinamide. By blocking NNMT, it increases nicotinamide availability for NAD+ biosynthesis via the salvage pathway, thereby boosting cellular energy metabolism and promoting adipocyte energy expenditure.

05

Effects reported in research

Reported outcomes, not promises. These come mostly from preclinical (cell or animal) research and have not been confirmed in human trials.

  • Increased cellular NAD+ levels
  • Enhanced fat cell energy expenditure
  • Reduced diet-induced obesity in models
  • Improved metabolic flexibility
06

Safety & unknowns

No human clinical trial data available. In diet-induced obese mice, systemic treatment with a methylquinolinium NNMT inhibitor did not reduce food intake or cause observable adverse effects. Long-term safety profile unknown. Not FDA-approved. Theoretical concerns about NNMT inhibition effects on methylation balance.

Unknowns. No randomized controlled trials in humans have been published, so human safety has not been established in controlled studies.

Informational only — not medical advice. peptidemeta publishes no dosing, protocols, or sourcing. Talk to a qualified clinician about any treatment decision.

07

Studies [1]

  1. Preclinical 2018

    Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice

    Neelakantan H, Vance V, Wetzel MD, et al. Biochemical Pharmacology

    Methylquinolinium NNMT inhibitors raised NAD+ and SAM and suppressed lipogenesis in adipocytes, and a potent inhibitor reduced body weight, white fat mass, and plasma cholesterol in diet-induced obese mice without changing food intake.

    [pubmed] [doi]

09

Status sources

Sources behind the tier, regulatory status, sequence and dates on this page.

10

Cite this entry

$ cite --format=apa

peptidemeta. (2026). 5-Amino-1MQ. In peptidemeta: The peptide library, ranked by evidence. Retrieved November 8, 2026, from https://peptidemeta.com/p/5-amino-1mq/

$ cite --format=bibtex 
@misc{peptidemeta-5-amino-1mq,
  title = {5-Amino-1MQ},
  author = {{peptidemeta}},
  year = {2026},
  howpublished = {\url{https://peptidemeta.com/p/5-amino-1mq/}},
  note = {Accessed 2026-11-08}
}

Accessed date reflects when you opened this page. Cite primary studies for scientific claims.

esc
↑↓ navigate ↵ open